Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120132 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis
A Phase 2 study, sponsored by Fovea Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 716
- Enrollment target
NCT01120132: Completed Phase 2 study, sponsored by Fovea Pharmaceuticals.
NCT01120132 is a Phase 2 study that has completed, run by Fovea Pharmaceuticals. The registered enrollment target is 716 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (438% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01120132, a Phase 2 study, has completed, sponsored by Fovea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 716 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of the administration of cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic conjunctivitis.
Primary Outcome
Patient-reported ocular itching and redness
Interventions
- DRUG Placebo
- DRUG CsA high dose
- DRUG CsA low dose
- DRUG PA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 716 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
What the finished NCT01120132 record still lists
NCT01120132 is an interventional study that assigns participants to a tested intervention. The registered 716 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (438% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01120132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01120132 about?
NCT01120132 is a clinical study titled "Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis". The purpose of this study is to determine the efficacy and safety of the administration of cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic conjunctivitis.
What is the current status of trial NCT01120132?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 716 participants. The study started on 2010-05. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01120132?
The interventions under investigation include: Placebo (DRUG), CsA high dose (DRUG), CsA low dose (DRUG), PA (DRUG).
Who is sponsoring clinical trial NCT01120132?
This trial is sponsored by Fovea Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01120132's enrollment target sits among peer trials
716 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia